multicenter cardiac arrhythmias suppression trial
cast
improved survival during use of moricizine
active ingredient
ethmozine
asymptomatic premature ventricular depolarizations in patients with a recent history of myocardial infarction
prospective study
using maximal dosages of moricizine
mean mg per day
patients with a history of sustained ventricular tachyarrhythmias
ejection fraction
significant proarrhythmic effect
lack of efficacy
experienced ventricular proarrhythmias
days
remaining patients
electrophysiologic testing
efficacy
patients
moricizine therapy
patient
ventricular proarrhythmia
complete av heart block
experienced recurrent ventricular tachycardia
cardiovascular
side effects
exacerbation of old
induction of new atrial
ventricular arrhythmias
heart failure
hypotension
syncope
moricizine-induced arrhythmias
conversion
sinus rhythm than nondrug-induced arrhythmias
proarrhythmic effect
serum potassium
calcium
magnesium concentrations
normal limits
moricizine therapy
alteration in ventricular conduction
including
new bundle branch patterns
patients
second-degree heart block
patients without baseline conduction abnormalities
preexisting abnormalities
third-degree heartblock
patients with baseline conduction dysfunction
independent risk factors for the development of moricizine cardiotoxicity
advanced age
coronary artery disease
history of myocardial infarction
ventricular ejection fraction
congestive heart failure
other cardiovascular effects
hypertension
chest pain
congestive heart failure
myocardial infarction
vasodilation
thrombophlebitis
gastrointestinal side effects
patients
manifesting as nausea
vomiting
diarrhea
abdominal discomfort
gastrointestinal effects
adverse reactions
discontinuation of therapy
patients
anorexia
bitter taste
dysphagia
flatulence
ileus
nervous system
side effects
dose-related dizziness
headache
other nervous system
side effects
hypoesthesias
paresthesias
anxiety
fatigue
disorders
tremor
abnormal gait
coordination
ataxia
dyskinesia
confusion
somnolence
agitation
seizure
coma
speech disorder
loss of memory
case
increased parkinsonism
moricizine
phenothiazine derivative
exacerbating
inducing
inducing parkinsonian symptoms
evidence of bone marrow toxicity
rare reports of thrombocytopenia
patients
other drugs with thrombocytopenia-associated potential
hematologic side effects
thrombocytopenia
hepatic side effects
elevated liver function tests
genitourinary side effects
chemical similarity of moricizine
active ingredient
ethmozine
phenothiazines
phenothiazines
urinary retention
genitourinary side effects
urinary retention
frequency
incontinence
impotence
libido
patients
drug fever
rechallenge
patients
hypothermia
temperature intolerance
vertigo
tinnitus
hypersensitivity side effects
rash
pruritus
urticaria
swelling of the lips
tongue
periorbital edema
cardiovascular effects
noncardiac side effects
patients
weeks of therapy
psychiatric symptoms of depression
euphoria
hallucinations
ocular side effects
nystagmus
diplopia
pain
vision
respiratory side effects
pulmonary embolism
hyperventilation
apnea
asthma
pharyngitis
cough
sinusitis
dermatologic symptoms of dry skin
rash